Aardvark Therapeutics (NASDAQ:AARD) Earns “Buy” Rating from BTIG Research

Aardvark Therapeutics (NASDAQ:AARD)‘s stock had its “buy” rating reaffirmed by analysts at BTIG Research in a note issued to investors on Tuesday,Benzinga reports. They presently have a $9.00 target price on the stock. BTIG Research’s price target would indicate a potential upside of 154.24% from the stock’s current price.

A number of other equities research analysts have also commented on AARD. HC Wainwright restated a “neutral” rating on shares of Aardvark Therapeutics in a report on Monday, March 2nd. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $47.00 target price on shares of Aardvark Therapeutics in a research note on Monday, January 12th. Oppenheimer lowered their target price on Aardvark Therapeutics from $35.00 to $21.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Stifel Nicolaus reissued a “hold” rating and issued a $6.00 price target (down from $24.00) on shares of Aardvark Therapeutics in a research note on Monday, March 2nd. Finally, Royal Bank Of Canada lowered Aardvark Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $18.00 to $6.00 in a report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Aardvark Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $25.09.

Aardvark Therapeutics Stock Performance

NASDAQ AARD opened at $3.54 on Tuesday. The business has a 50 day simple moving average of $10.36 and a 200 day simple moving average of $11.63. Aardvark Therapeutics has a 52-week low of $3.52 and a 52-week high of $17.94. The stock has a market cap of $77.24 million and a price-to-earnings ratio of -1.21.

Aardvark Therapeutics (NASDAQ:AARD) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.81) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.81).

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Aardvark Therapeutics in the second quarter valued at $42,000. China Universal Asset Management Co. Ltd. bought a new stake in Aardvark Therapeutics during the 4th quarter worth about $47,000. Persistent Asset Partners Ltd acquired a new position in shares of Aardvark Therapeutics during the 4th quarter worth about $56,000. New York State Common Retirement Fund acquired a new position in shares of Aardvark Therapeutics during the 2nd quarter worth about $99,000. Finally, MetLife Investment Management LLC bought a new position in shares of Aardvark Therapeutics in the 4th quarter valued at about $102,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.